Sanofi Acquires Kymab for $1.1 Billion Upfront to Expand Immune Disease Portfolio

Last YearAcquisitionFollowing U.S. biotechnology company Principia Biopharma, Sanofi today announced inImmune DiseasesAnother Milestone Achieved in Therapeutic Portfolio Strategy.

Foreign media reported on the 11th that Sanofi announced the acquisition of Kymab for an upfront payment of approximately $1.1 billion, with the deal expected to close in the first half of 2021. Under the agreement, Sanofi will initially pay $1.1 billion and may pay up to an additional $350 million upon achieving certain milestones. Through this acquisition, Sanofi will obtain full global rights to Kymab’s lead product candidate, KY10055, thereby gaining access to itsAntibodyNew Technologies and Research Capabilities.

It is reported that KY10055 is a fully human monoclonal antibody targeting OX40L, a key regulator of the immune system. Last August, KY10055 met both primary endpoints in a Phase 2a clinical trial involving patients with moderate-to-severe atopic dermatitis whose condition was not adequately controlled by topical corticosteroids. The primary endpoints were defined as the Eczema Area and Severity Index (EASI) score and other objective clinical measures.

Kymab, the developer of this product, is a clinical-stage biopharmaceutical company headquartered in Cambridge, UK, specializing in the development of fully human monoclonal antibodies for immune-mediated diseases and immuno-oncology. Reportedly, Kymab currently has eight R&D pipelines in place. Among these, the most advanced candidates, aside from KY1005, include the anti-tumor product KY1044, a monoclonal antibody targeting ICOS. Currently in Phase 1/2 clinical development, KY1044 can be administered as monotherapy or in combination with an anti-PD-L1 agent.

Bloomberg reported that, influenced by this news, Sanofi's stock price rose approximately 1% on the Paris Stock Exchange to €79.19.

In fact, this is not the first time Sanofi has expanded its presence in the field of immunological disease treatment through acquisitions. The most recent instance occurred last August, when Sanofi proposed to acquire the U.S. biotechnology company Principia Biopharma for $3.4 billion. Through this acquisition, Sanofi gained ownership of drugs developed by Principia Biopharma, including SAR442168, a BTK inhibitor for the treatment of multiple sclerosis and other central nervous system disorders.

At that time, Sanofi CEO Paul Hudson stated that the drug could potentially capture nearly half of the market share for the treatment of such diseases in the future, amounting to approximately $10 billion. Furthermore, the acquisition of Principia Biopharma aligns with Sanofi’s current strategy toward high-growthTransitionmatch the direction.

Since Paul Hudson assumed the role of CEO at Sanofi, the company has gradually shifted its R&D focus away from areas such as diabetes and cardiovascular diseases, redirecting investments toward established innovative fields, including oncology and autoimmune disease treatments.

This article is sourced from Yiou, an original piece by author Lin Yiling. For reprints or collaborations, please click here.Reprint Notice, Unauthorized reproduction will be subject to legal action.